Compare · ABSI vs MEDP
ABSI vs MEDP
Side-by-side comparison of Absci Corporation (ABSI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $15.31B, about 9.6x ABSI ($1.59B).
- Over the past year, ABSI is up 299.2% and MEDP is up 71.4% - ABSI leads by 227.8 points.
- ABSI has been more active in the news (9 items in the past 4 weeks vs 5 for MEDP).
- MEDP has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Medpace Holdings Inc.
- Price
- $10.24+0.10%
- $536.16+1.20%
- Market cap
- $1.59B
- $15.31B
- 1M return
- +57.54%
- +12.89%
- 1Y return
- +299.22%
- +71.39%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 9
- 5
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ABSI
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Chief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)
- SEC Form 8-K filed by Absci Corporation
- SEC Form 424B5 filed by Absci Corporation
- Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
- Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits
- Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
- The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.